KUALA LUMPUR: Pharmaceutical outfit Y.S.P.SOUTHEAST ASIA HOLDING [] Bhd is eyeing to set up a manufacturing facility in Indonesia in line with its regional expansion plans.
Its chairman Datuk Dr Anis Ahmad said that while Indonesia presented exciting prospects for the group to set up a manufacturing facility, nothing has been finalised as yet and it is too preliminary at this stage to provide details of this next expansion project.
In a statement Tuesday, June 21, Dr Anis said notwithstanding that, YSP was poised for its next stage of growth regionally now that the expansion of its local Bangi plant and Vietnam manufacturing facility had been successfully completed.
He said the new manufacturing facility for production of sterile products namely eye-drops and injectables at its Bangi plant was now under qualification.
Meanwhile, its veterinary factory in Nhon Trach 3 Industrial Zone in Dong Nai Province, Vietnam has also commenced operations, he said.
'YSP is always on the look out to carve our niche and capitalise on opportunities presented by the expected competitive environment that will be brought about by increasing patent expiries.'
'Patent expiries open up windows of opportunities for us and YSP is also in a state of readiness on the local front to ride on this new wave of prospects and at the same time, be a significant contributor towards the realisation of the Government's aspiration in making Malaysia a quality generics pharmaceuticals hub,' he said.
Dr Anis said he was optimistic of YSP playing a significant role in this aspect as it was already one of the top five largest manufacturers of generic pharmaceuticals in the country.
It currently manufactures, distributes, and exports over 400 products comprising pharmaceutical, healthcare, veterinary and aquatic range in the form of tablets, capsules, suppositories, liquid preparations, injectables, powder, gel and cream.
Its chairman Datuk Dr Anis Ahmad said that while Indonesia presented exciting prospects for the group to set up a manufacturing facility, nothing has been finalised as yet and it is too preliminary at this stage to provide details of this next expansion project.
In a statement Tuesday, June 21, Dr Anis said notwithstanding that, YSP was poised for its next stage of growth regionally now that the expansion of its local Bangi plant and Vietnam manufacturing facility had been successfully completed.
He said the new manufacturing facility for production of sterile products namely eye-drops and injectables at its Bangi plant was now under qualification.
Meanwhile, its veterinary factory in Nhon Trach 3 Industrial Zone in Dong Nai Province, Vietnam has also commenced operations, he said.
'YSP is always on the look out to carve our niche and capitalise on opportunities presented by the expected competitive environment that will be brought about by increasing patent expiries.'
'Patent expiries open up windows of opportunities for us and YSP is also in a state of readiness on the local front to ride on this new wave of prospects and at the same time, be a significant contributor towards the realisation of the Government's aspiration in making Malaysia a quality generics pharmaceuticals hub,' he said.
Dr Anis said he was optimistic of YSP playing a significant role in this aspect as it was already one of the top five largest manufacturers of generic pharmaceuticals in the country.
It currently manufactures, distributes, and exports over 400 products comprising pharmaceutical, healthcare, veterinary and aquatic range in the form of tablets, capsules, suppositories, liquid preparations, injectables, powder, gel and cream.
No comments:
Post a Comment